Quality of life in low-grade glioma patients receiving temozolomide.

@article{Liu2009QualityOL,
  title={Quality of life in low-grade glioma patients receiving temozolomide.},
  author={R W Liu and Karla Solheim and Mei-Yin C Polley and Kathleen R. Lamborn and Margaretta S Page and Anne Fedoroff and Jane E. Rabbitt and Nicholas A. Butowski and Michael Prados and Susan M. Chang},
  journal={Neuro-oncology},
  year={2009},
  volume={11 1},
  pages={59-68}
}
The purpose of this study was to describe the quality of life (QOL) of low-grade glioma (LGG) patients at baseline prior to chemotherapy and through 12 cycles of temozolomide (TMZ) chemotherapy. Patients with histologically confirmed LGG with only prior surgery were given TMZ for 12 cycles. QOL assessments by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) were obtained at baseline prior to chemotherapy and at 2-month intervals while receiving TMZ. Patients with LGG at baseline… CONTINUE READING